ArticleInflammopharmacology2026
Usnic acid attenuates inflammation and joint damage in Freund's complete adjuvant-induced arthritis in rats.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and functional disability. Usnic acid (UA), a lichen‑derived secondary metabolite, has shown anti‑inflammatory and antioxidant potential in preclinical models. This study evaluated the effects of UA in Freund's complete adjuvant (FCA)‑induced arthritis in rats and its impact on key inflammatory and oxidative biomarkers. Arthritis was induced by a single subplantar injection of FCA (0.15 mL), followed by oral administration of UA (25, 50, 100 mg/kg) and the reference drug piroxicam (10 mg/kg) for 15 days, with an additional group receiving HDUA (100 mg/kg) plus piroxicam. Disease severity and treatment response were assessed by measuring body weight, paw thickness, arthritic and joint stiffness scores, hematological indices, liver and kidney function markers, oxidative stress parameters (SOD, CAT, MDA), pro‑inflammatory cytokine and signaling mRNA expression (TNF‑α, IL‑1β, IL‑6, NF‑κB, COX‑2), and ankle joint histopathology and radiology. UA attenuated (p < 0.0001) FCA‑induced weight loss and reduced paw edema, arthritic scores, and joint stiffness versus arthritic controls, while improving RBC count and Hb and decreasing platelet count, TLC, urea, and creatinine (p < 0.001). UA also increased SOD and CAT activities, reduced MDA (p < 0.001), downregulated TNF‑α, IL‑1β, IL‑6, NF‑κB, and COX‑2 mRNA, and improved joint histology and radiographic appearance. UA thus exhibits anti‑inflammatory and antioxidant properties and represents a promising lead for further preclinical evaluation in RA, although additional studies are needed to better define its safety profile.
Indexed as
Identifiers
41893949What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.